N/A
Manufactured by Pacira Pharmaceuticals, Inc.
15,404 FDA adverse event reports analyzed
Last updated: 2026-04-14
BUPIVACAINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Pacira Pharmaceuticals, Inc.. The most commonly reported adverse reactions for BUPIVACAINE include OFF LABEL USE, PAIN, DRUG INEFFECTIVE, HYPOTENSION, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BUPIVACAINE.
Out of 9,090 classified reports for BUPIVACAINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 15,404 FDA FAERS reports that mention BUPIVACAINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, PAIN, DRUG INEFFECTIVE, HYPOTENSION, NAUSEA, HYPOAESTHESIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Pacira Pharmaceuticals, Inc. in connection with BUPIVACAINE. Always verify the specific product and NDC with your pharmacist.